(SeaPRwire) – NEW YORK, May 14, 2026 — HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference in New York City as follows:
Date: Thursday, June 4, 2026
Time: 7:35AM EDT
Webcast: Click Here
To schedule a one-on-one meeting with Healios, please contact your Jefferies representative at healthcareconference@jefferies.com.
The live and archived webcast will be available on the Healios website, with the replay accessible for 60 days.
About Healios:
HEALIOS K.K. is Japan’s leading clinical-stage biotechnology company leveraging the potential of stem cells in regenerative medicine. The company aims to deliver innovative therapies for patients with diseases lacking effective treatment options. A pioneer in regenerative medicine development in Japan, Healios owns proprietary global platforms utilizing both somatic stem cells and iPS cells.
In the somatic stem cell field, Healios is developing HLCM051 (invimestrocel), a proprietary cell therapy composed of multipotent adult progenitor cells (“MAPCs”) sourced from the bone marrow of healthy adult donors. HLCM051 has demonstrated strong anti-inflammatory and immunomodulatory effects across various disease conditions, is consistently manufactured at scale using 3D bioreactors, and has shown safety and potential efficacy in hundreds of patients across multiple indications. Healios is advancing HLCM051 globally for the treatment of ARDS, trauma, and ischemic stroke.
In the iPSC regenerative medicine field, Healios has developed HLCN061, a next-generation NK cell therapy for solid tumors that has been functionally enhanced through gene modification. These cells have shown potent anti-tumor activity in animal models, are produced using a scalable 3D bioreactor manufacturing process, and are currently being prepared for initial human trials in partnership with Akatsuki Therapeutics, Inc. The company has also created a proprietary, gene-edited “universal donor” induced pluripotent stem cell line to support the development of next-generation regenerative therapies in immuno-oncology, ophthalmology, liver diseases, and other areas with significant unmet medical needs.
Healios was founded in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).
https://www.healios.co.jp/en
Contact:
U.S. Investor Relations:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Richard Kincaid
Executive Officer and Chief Financial Officer
E-mail: ir@healios.jp
| Company Name: | HEALIOS K.K. |
| Representative: | Hardy TS Kagimoto, Chairman & CEO |
| (TSE Growth Code: 4593) |
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.
